| 2026-01-26 | +36.5% | news | Yahoo Finance | Does Sabirnetug’s Phase 2 Extension and Insider Stock Sales Alter the Bull Case for ABOS? - Yahoo Finance |
| 2026-01-26 | +36.5% | news | StocksToTrade | Acumen Pharmaceuticals’ Share Volatility: Insight Into Recent Developments - StocksToTrade |
| 2023-05-09 | +35.8% | legal | SEC EDGAR | ABOS 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-01-27 | +34.7% | news | simplywall.st | Are Insider Tax-Related Sales Misaligned With Acumen Pharmaceuticals’ (ABOS) Alzheimer’s Trial Progress Narrative? - simplywall.st |
| 2026-01-27 | +34.7% | news | Yahoo Finance | Assessing Acumen Pharmaceuticals (ABOS) Valuation After New Phase 2 ALTITUDE-AD Trial Developments - Yahoo Finance |
| 2023-07-17 | +26.3% | legal | SEC EDGAR | ABOS 8-K: 2.02 (SEC Filing) |
| 2023-07-17 | +26.3% | legal | SEC EDGAR | ABOS 8-K: 7.01, 8.01 (SEC Filing) |
| 2023-07-18 | -24.7% | news | The Motley Fool | Why Shares of Acumen Pharmaceuticals Are Down Tuesday - The Motley Fool |
| 2024-11-12 | -21.2% | earnings | Seeking Alpha | Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript |
| 2024-11-12 | -21.2% | earnings | Seeking Alpha | Acumen Pharmaceuticals GAAP EPS of -$0.50 misses by $0.13 |
| 2024-11-12 | -21.2% | legal | SEC EDGAR | ABOS 8-K: 2.02, 7.01 (SEC Filing) |
| 2021-11-15 | -17.6% | legal | SEC EDGAR | ABOS 8-K: 2.02 and (SEC Filing) |
| 2022-03-28 | -16.7% | legal | SEC EDGAR | ABOS 8-K: 2.02 and (SEC Filing) |
| 2026-04-01 | +13.6% | legal | Stock Titan | [EFFECT] Acumen Pharmaceuticals, Inc. SEC Filing - Stock Titan |
| 2026-04-01 | +13.6% | news | Stock Titan | Acumen Pharmaceuticals (NASDAQ: ABOS) registers 10.83M resale shares - Stock Titan |
| 2026-03-31 | +12.8% | news | Zacks | Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
| 2026-03-31 | +12.8% | news | Yahoo Finance | Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance |
| 2023-02-01 | -12.1% | legal | SEC EDGAR | ABOS 8-K: 7.01, 8.01 (SEC Filing) |
| 2026-03-27 | -12.1% | earnings | Moby | Acumen Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary |
| 2026-03-27 | -12.1% | news | Seeking Alpha | Acumen Pharmaceuticals files to sell 10.83M shares of common stock for holders |
| 2025-08-12 | -12.0% | expansion | Seeking Alpha | Acumen expects ALTITUDE-AD Phase II top line results in late 2026 as JCR partnership advances next-generation Alzheimers candidates |
| 2025-08-12 | -12.0% | earnings | Seeking Alpha | Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript |
| 2025-08-12 | -12.0% | earnings | Seeking Alpha | Acumen Pharmaceuticals GAAP EPS of -$0.68 misses by $0.16 |
| 2025-08-12 | -12.0% | legal | SEC EDGAR | ABOS 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-03-17 | -11.4% | news | Exec Edge | Acumen Pharma Presents Brain Delivery Studies at Alzheimer’s and Parkinson’s Diseases Conference 2026 |
| 2026-03-17 | -11.4% | news | GlobeNewswire | Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026 |
| 2026-03-17 | -11.4% | news | Stock Titan | Mouse study boosts brain delivery of Acumen’s Alzheimer’s antibody - Stock Titan |
| 2024-05-14 | +11.4% | earnings | Seeking Alpha | Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript |
| 2024-05-14 | +11.4% | earnings | Seeking Alpha | Acumen Pharmaceuticals GAAP EPS of -$0.25 |
| 2024-05-14 | +11.4% | legal | SEC EDGAR | ABOS 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-03-26 | -10.6% | earnings | GuruFocus.com | Acumen Pharmaceuticals Inc (ABOS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... |
| 2026-03-26 | -10.6% | earnings | MarketBeat | Acumen Pharmaceuticals Q4 Earnings Call Highlights |
| 2026-03-26 | -10.6% | news | GlobeNewswire | Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights |
| 2026-03-26 | -10.6% | news | Seeking Alpha | Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding |
| 2026-03-26 | -10.6% | earnings | Seeking Alpha | Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript |
| 2026-03-26 | -10.6% | earnings | Seeking Alpha | Acumen Pharmaceuticals GAAP EPS of -$2.00 beats by $0.02 |
| 2026-03-26 | -10.6% | legal | SEC EDGAR | ABOS 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-03-26 | -10.6% | analyst | Investing.com | Cantor Fitzgerald reiterates Acumen Pharmaceuticals stock rating - Investing.com |
| 2026-03-26 | -10.6% | news | Stock Titan | Alzheimer’s drug readout due in late 2026 as Acumen targets 2027 filing - Stock Titan |
| 2026-03-26 | -10.6% | news | Stock Titan | 10.8M Acumen shares registered for resale (NASDAQ: ABOS) - Stock Titan |
| 2026-03-26 | -10.6% | earnings | Quiver Quantitative | ACUMEN PHARMACEUTICALS ($ABOS) Releases Q4 2025 Earnings - Quiver Quantitative |
| 2023-11-13 | +10.3% | legal | SEC EDGAR | ABOS 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-09-30 | +10.0% | news | simplywall.st | Promising Penny Stocks To Watch In September 2025 - simplywall.st |
| 2023-01-04 | +9.3% | legal | SEC EDGAR | ABOS 8-K: 5.02 (SEC Filing) |
| 2026-04-07 | -9.1% | news | Stock Titan | James B. Murray Jr. discloses 3.61M shares in Acumen Pharmaceuticals (NASDAQ: ABOS) - Stock Titan |
| 2024-02-01 | -9.0% | legal | SEC EDGAR | ABOS 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-04-23 | -8.9% | news | Stock Titan | Acumen (NASDAQ: ABOS) seeks approval for major equity plan expansion - Stock Titan |
| 2021-11-14 | -8.5% | analyst | eToro | ABOS Stock Price | Analyst Target 6.67 & Consensus - eToro |
| 2026-01-09 | -8.3% | news | Investing.com | Acumen Pharma president Doherty sells $15k in ABOS stock - Investing.com |
| 2021-08-26 | +8.2% | earnings | MarketBeat | Acumen Pharmaceuticals (ABOS) Short Interest & Short Float | Updated Apr 2026 $ABOS - MarketBeat |
| 2023-05-12 | +8.0% | news | CoinCodex | Acumen Pharmaceuticals, Inc. (ABOS) Stock Forecast & Price Prediction 2026–2030 - CoinCodex |
| 2022-05-16 | +8.0% | legal | SEC EDGAR | ABOS 8-K: 2.02 and (SEC Filing) |
| 2022-10-24 | -7.7% | legal | SEC EDGAR | ABOS 8-K: 8.01 and (SEC Filing) |
| 2023-11-09 | -7.6% | legal | SEC EDGAR | ABOS 8-K: 1.01 (SEC Filing) |
| 2025-05-13 | -7.5% | earnings | Seeking Alpha | Acumen Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call Presentation |
| 2025-05-13 | -7.5% | news | Seeking Alpha | Acumen targets ALTITUDE-AD Phase 2 topline results in late 2026 while advancing subcutaneous Sabirnetug development |
| 2025-05-13 | -7.5% | earnings | Seeking Alpha | Acumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call Transcript |
| 2025-05-13 | -7.5% | earnings | Seeking Alpha | Acumen Pharmaceuticals GAAP EPS of -$0.48 beats by $0.06 |
| 2025-05-13 | -7.5% | legal | SEC EDGAR | ABOS 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-07-15 | -7.3% | legal | SEC EDGAR | ABOS 8-K: 1.01, 7.01 (SEC Filing) |
| 2024-03-27 | +7.2% | news | Seeking Alpha | Acumen Pharmaceuticals files for $200M mixed shelf offering |
| 2025-03-19 | -7.1% | news | Seeking Alpha | Acumen posts safety data from early stage trial for its Alzheimer's drug |
| 2026-03-16 | -6.8% | legal | SEC EDGAR | ABOS 8-K: 1.01, 3.02, 7.01 (SEC Filing) |
| 2026-03-16 | -6.8% | legal | Stock Titan | Alzheimer’s brain drug: Acumen secures $35.75M after 40x uptake - Stock Titan |
| 2026-03-16 | -6.8% | news | TipRanks | Acumen Raises Capital to Advance Enhanced Brain Delivery - TipRanks |
| 2026-03-16 | -6.8% | news | TradingView | Acumen Pharmaceuticals Raises $35.75 Million in Private Placement to Fund EBD Program - TradingView |
| 2026-03-19 | -6.6% | news | GlobeNewswire | Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026 |
| 2026-03-19 | -6.6% | expansion | MarketBeat | Acumen Pharmaceuticals Spotlights Sabirnetug Phase II Progress, JCR Brain-Delivery Partnership at Conference |
| 2026-03-19 | -6.6% | news | Stock Titan | Alzheimer's drug developer Acumen sets March 26 results webcast - Stock Titan |
| 2025-11-12 | -6.5% | news | Seeking Alpha | Acumen anticipates ALTITUDE-AD top line results in late 2026 as EBD program progresses |
| 2025-11-12 | -6.5% | earnings | Seeking Alpha | Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call Transcript |
| 2025-11-12 | -6.5% | earnings | Seeking Alpha | Acumen Pharmaceuticals GAAP EPS of -$0.44 beats by $0.14 |
| 2025-11-12 | -6.5% | legal | SEC EDGAR | ABOS 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-01-03 | -6.3% | legal | SEC EDGAR | ABOS 8-K: 5.02 (SEC Filing) |
| 2025-07-12 | +6.2% | news | TradingView | ABOS Options Chain — NASDAQ:ABOS - TradingView |
| 2024-09-26 | +5.7% | news | Seeking Alpha | Acumen Pharmaceuticals extends collaboration with Lonza |
| 2024-03-17 | -5.4% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2022-11-14 | -5.1% | legal | SEC EDGAR | ABOS 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-03-27 | +4.9% | news | Seeking Alpha | Acumen Pharmaceuticals outlines ALTITUDE AD Phase 2 plans and late 2026 data timeline |
| 2025-03-27 | +4.9% | earnings | Seeking Alpha | Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call Transcript |
| 2025-03-27 | +4.9% | news | Seeking Alpha | Acumen Pharmaceuticals reports FY results |
| 2025-03-27 | +4.9% | legal | SEC EDGAR | ABOS 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-01-07 | -4.8% | executive | Investing.com | Acumen Pharma CFO Zuga sells $29k in ABOS stock - Investing.com |
| 2024-03-26 | -4.2% | legal | SEC EDGAR | ABOS 8-K: 2.02 and (SEC Filing) |
| 2022-08-15 | +4.0% | legal | SEC EDGAR | ABOS 8-K: 2.02, 5.02 (SEC Filing) |
| 2022-08-15 | +4.0% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Acumen Pharmaceuticals (ABOS) - Zacks Investment Research |
| 2026-01-23 | +4.0% | news | Investing.com | Acumen Pharma CMO Siemers sells $5.8k in ABOS stock - Investing.com |
| 2026-01-23 | +4.0% | news | Investing.com | Acumen Pharmaceuticals CLO sells shares worth $16,720 - Investing.com |
| 2025-04-02 | -3.8% | news | Stock Titan | Game-Changing Trial Screening Method: Acumen Advances Alzheimer's Research with pTau217 Innovation - Stock Titan |
| 2024-08-13 | -3.7% | earnings | Seeking Alpha | Acumen Pharmaceuticals, Inc. (ABOS) Q2 2024 Earnings Call Transcript |
| 2024-08-13 | -3.7% | earnings | Seeking Alpha | Acumen Pharmaceuticals GAAP EPS of -$0.34 misses by $0.05 |
| 2024-08-13 | -3.7% | legal | SEC EDGAR | ABOS 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-11-26 | +3.7% | news | Stocktwits | Acumen Pharmaceuticals Inc (ABOS) News, Articles, Events & Latest Updates - Stocktwits |
| 2025-11-10 | +3.0% | legal | SEC EDGAR | ABOS 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-04-22 | -2.8% | analyst | ChartMill | ABOS Forecast, Price Target & Analyst Ratings | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill |
| 2024-03-19 | +2.8% | legal | SEC EDGAR | ABOS 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-01-28 | +2.8% | news | Investing.com | Acumen Pharma CLO sells $53k in shares after option exercise - Investing.com |
| 2025-11-28 | -2.7% | news | Yahoo Finance | Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching - Yahoo Finance |
| 2023-03-27 | +2.3% | legal | SEC EDGAR | ABOS 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-06-21 | +2.1% | news | Yahoo Finance | Is Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) the Best Halal Stock According to Hedge Funds? - Yahoo Finance |
| 2022-10-17 | -2.1% | analyst | TradingView | ABOS Forecast — Price Target — Prediction for 2027 - TradingView |
| 2023-08-08 | -2.0% | legal | SEC EDGAR | ABOS 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-08-08 | -2.0% | news | CoinCodex | Acumen Pharmaceuticals, Inc. (ABOS) Dividend History, Date, and Yield - CoinCodex |
| 2021-08-16 | +2.0% | legal | SEC EDGAR | ABOS 8-K: 2.02 and (SEC Filing) |
| 2026-03-30 | +1.9% | news | Zacks | Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? |
| 2026-03-30 | +1.9% | news | Yahoo Finance | Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance |
| 2026-03-30 | +1.9% | news | qz.com | Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? - qz.com |
| 2026-03-30 | +1.9% | news | Zacks Investment Research | Should I buy Acumen Pharmaceuticals (ABOS) - Zacks Investment Research |
| 2026-03-30 | +1.9% | earnings | Zacks Investment Research | What date does Acumen Pharmaceuticals's (ABOS) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research |
| 2026-04-21 | -1.4% | earnings | MarketBeat | Acumen Pharmaceuticals (NASDAQ:ABOS) Trading 0.7% Higher - Still a Buy? - MarketBeat |
| 2024-04-04 | -1.3% | news | Seeking Alpha | Acumen Pharmaceuticals partners with Lonza to advance sabirnetug for the treatment of Alzheimers |
| 2025-04-03 | +1.0% | news | Intellectia AI | ABOS Forecast — Price Prediction for 2026. Should I Buy ABOS? - Intellectia AI |
| 2024-07-30 | -0.8% | news | Seeking Alpha | Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's |
| 2023-07-20 | +0.5% | legal | SEC EDGAR | ABOS 8-K: 1.01, 8.01 (SEC Filing) |
| 2023-04-27 | -0.2% | legal | SEC EDGAR | ABOS 8-K: 1.01, 8.01 (SEC Filing) |
| 2025-09-03 | +0.1% | news | Seeking Alpha | Acumen Pharmaceuticals, Inc. (ABOS) Presents At Citi's Biopharma Back To School Conference Transcript |
| 2025-09-03 | +0.1% | news | Seeking Alpha | Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citi's Biopharma Back to School Conference - Slideshow |
| 2021-07-02 | -0.1% | earnings | MarketBeat | Acumen Pharmaceuticals (ABOS) Earnings Date and Reports 2026 $ABOS - MarketBeat |
| 2021-07-02 | -0.1% | news | TradingView | Technical Analysis of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - TradingView |
| 2021-07-01 | — | earnings | MarketBeat | Acumen Pharmaceuticals (ABOS) Stock Price, News & Analysis $ABOS - MarketBeat |